vs
Marygold Companies, Inc.（MGLD）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
SUTRO BIOPHARMA, INC.的季度营收约是Marygold Companies, Inc.的1.5倍（$11.6M vs $7.6M），Marygold Companies, Inc.同比增速更快（-4.5% vs -21.4%），过去两年Marygold Companies, Inc.的营收复合增速更高（-1.5% vs -5.4%）
Marygold Companies, Inc.是一家总部位于美国的多元化控股企业，核心业务覆盖金融服务、特种制造及消费品三大板块，主要面向北美市场开展运营，通过对旗下子公司的战略投资与运营优化实现长期价值增长。
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
MGLD vs STRO — 直观对比
营收规模更大
STRO
是对方的1.5倍
$7.6M
营收增速更快
MGLD
高出16.8%
-21.4%
两年增速更快
MGLD
近两年复合增速
-5.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.6M | $11.6M |
| 净利润 | $-576.0K | — |
| 毛利率 | 74.0% | — |
| 营业利润率 | -8.3% | — |
| 净利率 | -7.5% | — |
| 营收同比 | -4.5% | -21.4% |
| 净利润同比 | 67.0% | 35.4% |
| 每股收益（稀释后） | $-0.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGLDSTRO
| Q4 25 | $7.6M | $11.6M | ||
| Q3 25 | $7.0M | $9.7M | ||
| Q2 25 | $7.2M | $63.7M | ||
| Q1 25 | $7.0M | $17.4M | ||
| Q4 24 | $8.0M | $14.8M | ||
| Q3 24 | $7.9M | $8.5M | ||
| Q2 24 | $8.3M | $25.7M | ||
| Q1 24 | $7.9M | $13.0M |
净利润MGLDSTRO
| Q4 25 | $-576.0K | — | ||
| Q3 25 | $-356.0K | $-56.9M | ||
| Q2 25 | $-1.5M | $-11.5M | ||
| Q1 25 | $-1.0M | $-76.0M | ||
| Q4 24 | $-1.7M | $-72.4M | ||
| Q3 24 | $-1.6M | $-48.8M | ||
| Q2 24 | $-1.9M | $-48.0M | ||
| Q1 24 | $-529.0K | $-58.2M |
毛利率MGLDSTRO
| Q4 25 | 74.0% | — | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 75.0% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 72.5% | — | ||
| Q1 24 | 70.5% | — |
营业利润率MGLDSTRO
| Q4 25 | -8.3% | — | ||
| Q3 25 | -18.2% | -499.9% | ||
| Q2 25 | -16.5% | -5.2% | ||
| Q1 25 | -21.4% | -393.8% | ||
| Q4 24 | -22.8% | -440.7% | ||
| Q3 24 | -27.4% | -797.2% | ||
| Q2 24 | -33.3% | -189.4% | ||
| Q1 24 | -18.7% | -435.0% |
净利率MGLDSTRO
| Q4 25 | -7.5% | — | ||
| Q3 25 | -5.1% | -586.6% | ||
| Q2 25 | -20.4% | -18.0% | ||
| Q1 25 | -14.4% | -436.6% | ||
| Q4 24 | -21.8% | -489.2% | ||
| Q3 24 | -20.1% | -572.6% | ||
| Q2 24 | -22.5% | -186.8% | ||
| Q1 24 | -6.7% | -447.5% |
每股收益（稀释后）MGLDSTRO
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $-0.01 | $-0.67 | ||
| Q2 25 | $-0.04 | $-0.14 | ||
| Q1 25 | $-0.02 | $-0.91 | ||
| Q4 24 | $-0.04 | $-27.63 | ||
| Q3 24 | $-0.04 | $-0.59 | ||
| Q2 24 | $-0.05 | $-0.59 | ||
| Q1 24 | $-0.01 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $141.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $22.7M | $-132.5M |
| 总资产 | $27.8M | $173.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MGLDSTRO
| Q4 25 | $11.6M | $141.4M | ||
| Q3 25 | $12.5M | $167.6M | ||
| Q2 25 | $12.8M | $205.1M | ||
| Q1 25 | $15.6M | $249.0M | ||
| Q4 24 | $14.9M | $316.9M | ||
| Q3 24 | $17.5M | $388.3M | ||
| Q2 24 | $15.0M | $375.6M | ||
| Q1 24 | $16.1M | $267.6M |
股东权益MGLDSTRO
| Q4 25 | $22.7M | $-132.5M | ||
| Q3 25 | $22.9M | $-87.3M | ||
| Q2 25 | $23.0M | $-32.1M | ||
| Q1 25 | $24.3M | $-25.8M | ||
| Q4 24 | $23.4M | $44.6M | ||
| Q3 24 | $25.5M | $111.2M | ||
| Q2 24 | $26.6M | $152.2M | ||
| Q1 24 | $28.4M | $98.0M |
总资产MGLDSTRO
| Q4 25 | $27.8M | $173.8M | ||
| Q3 25 | $28.4M | $209.7M | ||
| Q2 25 | $30.4M | $262.4M | ||
| Q1 25 | $33.5M | $321.4M | ||
| Q4 24 | $33.0M | $387.2M | ||
| Q3 24 | $35.9M | $451.8M | ||
| Q2 24 | $32.9M | $489.0M | ||
| Q1 24 | $33.7M | $403.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-908.0K | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MGLDSTRO
| Q4 25 | $-908.0K | $-177.2M | ||
| Q3 25 | $-533.0K | $-38.2M | ||
| Q2 25 | $-3.3M | $-44.7M | ||
| Q1 25 | $-1.2M | $-67.9M | ||
| Q4 24 | $-770.0K | $-71.7M | ||
| Q3 24 | $-893.0K | $-64.5M | ||
| Q2 24 | $-1.9M | $9.5M | ||
| Q1 24 | $-658.0K | $-64.7M |
自由现金流MGLDSTRO
| Q4 25 | — | — | ||
| Q3 25 | $-562.0K | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-776.0K | — | ||
| Q3 24 | $-940.0K | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | — | — |
自由现金流率MGLDSTRO
| Q4 25 | — | — | ||
| Q3 25 | -8.1% | — | ||
| Q2 25 | -46.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -9.7% | — | ||
| Q3 24 | -11.9% | — | ||
| Q2 24 | -23.8% | — | ||
| Q1 24 | — | — |
资本支出强度MGLDSTRO
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
STRO
暂无分部数据
